Research programme: ricin poisoning antidotes - Cangene

Drug Profile

Research programme: ricin poisoning antidotes - Cangene

Alternative Names: Ricin immunoglobulin - Cangene

Latest Information Update: 28 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cangene Corporation; Twinstrand Therapeutics
  • Developer Emergent BioSolutions
  • Class Immunoglobulins; Monoclonal antibodies; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ricin poisoning

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 14 Sep 2006 This programme is still in active development
  • 25 Mar 2004 Preclinical trials in Ricin poisoning in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top